The development of treatments for liver fibrosis and other fatty liver diseases is predicted to be the focus of increased research by numerous private research organisations, which is santicipated to fuel market expansion for liver fibrosis treatments. The global market for liver fibrosis treatment is anticipated to rise as a result of key companies' increased research and development efforts in pre-clinical and clinical studies to create novel treatment methods for liver fibrosis regimes. For example, Protagonist Therapeutics, Inc.'s PTG-300, an injectable subcutaneous product, received Orphan Drug Designation from the U.S. Food and Drug Administration in March 2018. For the prospective treatment of beta-thalassemia, the PTG-300 is now in the clinical development stage. It can also be used to treat liver fibrosis. In addition, the biopharmaceutical company Gilead Sciences, Inc. published the Phase II results for Selonsertib: GS-0976 in Nonalcoholic Steatohepatitis (NASH) stage F3 liver fibrosis in October 2017. These investigations showed that GS-0976 significantly reduced the amount of liver fibrosis and fat in the liver.
As per Coherent Market Insights, The market for treating Liver Fibrosis is predicted to reach US$ 14.7 billion in 2022 and grow at a CAGR of 10.8% during the following five years (2022-2030).
Market Players in the Liver Fibrosis Treatment Industry:
1. Merck & Co., Inc.,
The business was founded in 1668, and Rahway, New Jersey serves as its corporate headquarters. Pharmaceuticals, vaccines, biologic therapies, and goods for animal health are all produced by Merck. The company announced in September 2022 that it will acquire the cattle management company Vence for an undisclosed sum and merge it with Merck Animal Health. Merck Animal Health acquired PrognostiX Poultry in February 2021.
2. Pfizer Inc.,
The company was established in 1849, and Manhattan, New York City, serves as its corporate headquarters. Pfizer conducts pharmaceutical and vaccine research and development that advances the fields of immunology, cancer, the heart, endocrinology, and neurology. In October 2022, the company successfully acquired Biohaven Pharma's calcitonin gene-related peptide programmes. In April 2021, Pfizer acquired Amplyx Pharmaceuticals, along with the antifungal medication fosmanogepix. (APX001).
3. Novartis AG
Cambridge, Massachusetts and Basel, Switzerland are home to Novartis AG, which was founded in March 1996. Novartis covers all varieties of drugs, including those that are prescribed, over-the-counter, for immunisations, diagnostics, eyewear, and veterinary care. Handling, marketing, operations, and research are a few of the duties that Novartis directly does through its businesses.
4. Johnson and Johnson
Corporate offices for Johnson & Johnson are located in New Brunswick, New Jersey. The company was founded there in 1886. Johnson & Johnson produces medical equipment, over-the-counter medicines, and consumer goods. In November 2021, the company announced that it would split into two publicly traded companies, one specialising in consumer items and the other in pharmaceuticals and medical technologies. According to the company, sales of the Covid-19 vaccine totaled $100 million in the first quarter of April 2021. In November 2022, Abiomed Inc. was purchased by Johnson & Johnson for $16.6 billion.
5. Gilead Sciences, Inc.
The business was established in 1987 and is based in Foster City, California, United States. The company's primary focus is on the development of antiviral medications for the treatment of COVID-19, hepatitis B, hepatitis C, flu, and HIV/AIDS. The company finished acquiring Tmunity Therapeutics through Kite Pharma in February 2023. In September 2020, Gilead declared it has struck an agreement to buy Immunomedics for $21 billion ($88 per share), obtaining control of the cancer therapy Trodelvy.
6. Bristol-Myers Squibb
The firm was founded in 1887 and is located in New York, United States. The therapeutic areas in which Bristol Myers Squibb produces prescription drugs and biologics include cancer, HIV/AIDS, cardiovascular illness, insulin, hepatitis, rheumatoid arthritis, and mental conditions. BMS said in June 2022 that it would pay $4.1 billion in cash to purchase Turning Point Therapeutics Inc.
7. FibroGen, Inc.
The firm was founded in 1993 and has its headquarters in San Francisco, California, United States. The mission of FibroGen, Inc., a pharmaceutical business with a research foundation, is to identify, create, and market innovative therapeutic molecules for the treatment of unmet medical needs that are of significant magnitude. When developing and promoting its products, the company has a global perspective.
*Definition: Liver fibrosis is a sign of another liver disorder rather than a distinct disease. Liver fibrosis by itself has no symptoms. In order to prevent or slow down the scarring of the liver, healthcare providers concentrate on treating the cause of liver fibrosis.
